ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 760 USD | -1.50% |
|
+3.41% | +30.38% |
| 05-10 | Cipla Open to Partner With Eli Lilly to Market Obesity Drugs in India | MT |
| 05-10 | Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows | RE |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 42.81B 58.51B | Sales 2025 * | 52.47B 71.71B | Capitalization | 684B 935B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 16.31B | Net income 2025 * | 16.55B 22.62B | EV / Sales 2024 * | 16.5 x |
| Net Debt 2024 * | 19.98B 27.31B | Net Debt 2025 * | 15.29B 20.89B | EV / Sales 2025 * | 13.3 x |
| P/E ratio 2024 * |
56.8
x | P/E ratio 2025 * |
40.9
x | Employees | 43,000 |
| Yield 2024 * |
0.68% | Yield 2025 * |
0.79% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
| 1 day | -1.50% | ||
| 1 week | +3.41% | ||
| Current month | -2.70% | ||
| 1 month | +0.05% | ||
| 3 months | +2.68% | ||
| 6 months | +27.15% | ||
| Current year | +30.38% |
1 week
736.00
784.00
1 month
718.30795.50
Current year
579.05800.78
1 year
419.80800.78
3 years
191.75800.78
5 years
101.36800.78
10 years
57.81800.78
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 0 M€ | +7.69% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 760 | -1.50% | 2,082,289 |
| 24-05-09 | 771.6 | -0.45% | 2,522,085 |
| 24-05-08 | 775 | -0.36% | 2,089,934 |
| 24-05-07 | 777.8 | +1.45% | 2,879,447 |
| 24-05-06 | 766.7 | +4.31% | 3,398,280 |
Delayed Quote Nyse, May 10, 2024 at 04:00 pm
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
760
USD
Average target price
850.4
USD
Spread / Average Target
+11.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B | |
| -2.71% | 159B |
- Stock Market
- Equities
- LLY Stock
